# Coleus forskohlii-extract verlaagt gewicht en triglyceriden bij overgewicht — 12-weken studie

*geplaatst 2026-09-08 · Cholesterol · Journal of the International Society of Sports Nutrition · doi 10.1080/15502783.2026.2725137 · https://hartvaat.nl/2026/12/30/coleus-forskohlii-extract-verlaagt-gewicht-en-triglyceriden-bij-overgewicht-12-w/*

Een 12-weken, dubbelblinde, gecontroleerde studie onderzocht de effecten van het supplement Forcslim (Coleus forskohlii-extract) op gewichtsverlies en het lipidenprofiel bij 60 personen met overgewicht. Na 12 weken vertoonde de interventiegroep een significante daling van het lichaamsgewicht (-1,93 kg) en de buikomtrek (-1,83 cm), vergeleken met placebo. Daarnaast daalden de triglyceriden en steeg het HDL-cholesterol, zonder ongunstige veiligheidsbevindingen. Hoewel de studie beperkt is in omvang, suggereert het resultaat dat dit extract een veilig alternatief kan zijn voor synthetische afvalkuren, met mogelijke cardiometabole voordelen.

## English: A 12-week, double-blind, quasi-randomized, placebo-controlled study to evaluate the efficacy and safety of

A 12-week, double-blind, placebo-controlled trial evaluated the effects of Coleus forskohlii extract (Forcslim) on weight loss and lipid profiles in 60 overweight adults. Compared with placebo, the supplement group achieved significant reductions in body weight (-1.93 kg) and waist circumference (-1.83 cm), alongside improved triglyceride and HDL cholesterol levels, with no safety concerns reported. While the study is limited by its small sample size and short duration, the findings suggest that this botanical extract may offer a safe adjunct for weight management with favorable cardiometabolic effects.

## Abstract (original, from the publication)

BACKGROUND: Overweight and obesity have emerged as a global epidemic, significantly impacting human health. Traditional usage and growing scientific evidence suggest that Coleus forskohlii extract (Forcslim) may aid in reducing excess body weight and fat. This study aimed to evaluate the efficacy and safety of Forcslim supplementation in overweight individuals. METHODS: A quasi-randomized, double-blind, placebo-controlled clinical trial was conducted in 60 overweight subjects aged 20-70 years over a period of 12 weeks. The participants were assigned to receive either Forcslim or placebo. The key outcome measures included body weight, body mass index (BMI), body composition, and anthropometric parameters. Additionally, lipid profile parameters and safety markers (including metabolic, hepatic, and cardiovascular indicators) were assessed throughout the study duration. RESULTS: Compared to the placebo group, the Forcslim group showed significant reductions in waist circumference (-1.83 cm; p < 0.01) and body weight (-1.93 kg; p < 0.001). Significant improvements in anthropometric parameters were observed exclusively in the Forcslim group. Furthermore, triglyceride (TG) levels were significantly reduced (p < 0.01), while high-density lipoprotein (HDL) levels showed a significant increase (p = 0.001). No clinically significant changes were observed in metabolic markers, liver and muscle enzyme levels, heart rate, blood pressure, or reported adverse effects, indicating a favorable safety profile. CONCLUSIONS: Forcslim demonstrated significant anti-obesity effects, including reductions in body weight, waist circumference, and improvements in the lipid profile. These findings suggest that C. forskohlii extract supplementation may serve as a safe and effective alternative to synthetic anti-obesity drugs.

Auteurs: Sadashiva Channangihalli Thimmegowda, Firoz Hirehal Hussain Mirza, Rajesh Venkataraman, Ravi B Nagarajaiah

---
Bron: Journal of the International Society of Sports Nutrition, https://doi.org/10.1080/15502783.2026.2725137. Bijgewerkt 2026-09-02T00:46:42Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.